Groups of victims once affected by the drug Thalidomide have recently issued a call regarding the rapid development of embryo genetic testing technology, urging countries to carefully assess its ethical and social impacts before expanding the application of such testing. These victims, who suffered congenital defects decades ago due to the drug, now worry that emerging reproductive technologies, if lacking adequate regulation, could once again cause irreversible harm to humanity.
Embryo genetic testing technologies, such as preimplantation genetic testing (PGT), are mainly used during in vitro fertilization (IVF) to screen embryos for chromosomal abnormalities or specific genetic diseases before implantation, in order to improve pregnancy success rates and reduce the risk of miscarriage. In recent years, with technological advances and falling costs, the scope of application of such testing has gradually expanded, and it has even begun to be used for non-medical purposes such as sex selection or screening for certain non-fatal traits, sparking ethical controversy.
Thalidomide victim organizations believe that although genetic testing helps prevent serious genetic diseases, excessive expansion of its application could lead to an excessive societal pursuit of "perfect babies," thereby discriminating against people with physical and mental disabilities and exacerbating social inequality. They call for clear ethical guidelines, legal regulations and public discussion mechanisms to be established before testing is expanded, ensuring that technological development is centered on human rights and social well-being rather than merely pursuing efficiency or commercial interests.
This call has also received support from some medical ethics experts. Experts point out that decisions about embryo genetic testing should respect couples' autonomy while providing adequate genetic counseling so that those involved understand the limitations and potential risks of testing. In addition, countries should strengthen cross-border regulatory coordination to avoid problems such as "reproductive tourism" arising from differences in regulations, ensuring that the application of the technology conforms to universal ethical standards.
For readers in Chinese-speaking regions, this issue is also of reference value. As assisted reproductive technology becomes increasingly widespread in Asia, whether the relevant ethical and legal frameworks are adequate will directly affect the choices and rights of countless families. The call from Thalidomide victims reminds us that while embracing technological progress, we must also remember the lessons of history, put people first, and proceed prudently.
Source: Newsbook. This article is a compiled report for general informational reference.
This article was prepared with AI assistance and reviewed by our editorial team before publication.
This content is for informational purposes only and does not constitute medical advice. Please consult a licensed physician. Content guidelines & editorial policy
News | Thalidomide victims call for a moratorium on expanding embryo genetic testing
Groups of victims once affected by the drug Thalidomide have recently issued a call regarding the rapid development of embryo genetic testing technology, urging countries to carefully assess its ethical and social impacts before expanding the application of such testing. These victims, who suffered congenital defects decades ago due to the drug, now worry that emerging reproductive technologies, if lacking adequate regulation, could once again cause irreversible harm to humanity.
Embryo genetic testing technologies, such as preimplantation genetic testing (PGT), are mainly used during in vitro fertilization (IVF) to screen embryos for chromosomal abnormalities or specific genetic diseases before implantation, in order to improve pregnancy success rates and reduce the risk of miscarriage. In recent years, with technological advances and falling costs, the scope of application of such testing has gradually expanded, and it has even begun to be used for non-medical purposes such as sex selection or screening for certain non-fatal traits, sparking ethical controversy.
Thalidomide victim organizations believe that although genetic testing helps prevent serious genetic diseases, excessive expansion of its application could lead to an excessive societal pursuit of "perfect babies," thereby discriminating against people with physical and mental disabilities and exacerbating social inequality. They call for clear ethical guidelines, legal regulations and public discussion mechanisms to be established before testing is expanded, ensuring that technological development is centered on human rights and social well-being rather than merely pursuing efficiency or commercial interests.
This call has also received support from some medical ethics experts. Experts point out that decisions about embryo genetic testing should respect couples' autonomy while providing adequate genetic counseling so that those involved understand the limitations and potential risks of testing. In addition, countries should strengthen cross-border regulatory coordination to avoid problems such as "reproductive tourism" arising from differences in regulations, ensuring that the application of the technology conforms to universal ethical standards.
For readers in Chinese-speaking regions, this issue is also of reference value. As assisted reproductive technology becomes increasingly widespread in Asia, whether the relevant ethical and legal frameworks are adequate will directly affect the choices and rights of countless families. The call from Thalidomide victims reminds us that while embracing technological progress, we must also remember the lessons of history, put people first, and proceed prudently.
Source: Newsbook. This article is a compiled report for general informational reference.